RLT

0.75

134.4%

88E

0.001

-50%

H2G

0.006

100%

NRZ

0.001

-50%

WOA

0.029

61.1%

TOU

0.008

-46.7%

PR2

0.079

33.9%

ALM

0.003

-40%

CTN

0.004

33.3%

CKA

0.036

-40%

BEZ

0.037

32.1%

ANR

0.007

-36.4%

STN

0.255

27.5%

DTM

0.004

-33.3%

SHO

0.028

27.3%

ECT

0.002

-33.3%

MLX

0.665

26.7%

NTM

0.002

-33.3%

AGR

0.049

25.6%

PUA

0.007

-30%

SMX

0.049

25.6%

OVT

0.005

-28.6%

AZY

0.47

25.3%

ID8

0.008

-27.3%

ADG

0.005

25%

CYB

0.073

-27%

LEG

0.01

25%

SLH

1.54

-22.2%

NMG

0.015

25%

OEC

0.09

-21.7%

VMC

0.12

25%

SNX

0.018

-21.7%

WSR

0.01

25%

RML

0.011

-21.4%

RWL

0.28

24.4%

RMS

2.2

-21.1%

EGR

0.155

24%

BSX

0.057

-20.8%

PSC

0.105

23.5%

CUE

0.1

-20%

PYC Therapeutics (ASX:PYC): Reports vision improvement in multiple RP11 patients

Published on Tuesday August 13 2024

YouTube Video VVVFRVZOQ01GU1J4RmEwQmIyd0tMUzBnLjN2MlJISUM5eWY0

PYC Therapeutics (ASX:PYC) has developed the only clinical-stage investigational drug candidate designed specifically for patients with the blinding eye disease Retinitis Pigmentosa type 11 (RP11).

PYC recently reported an improvement in vision in 2 patients with RP11
PYC will announce further results from the ongoing multiple dose studies of VP-001 in Q4 2024
PYC is now preparing for a registrational trial that will be designed to support a new drug application and commercial launch of this drug candidate 4

ASX announcement https://announcements.asx.com.au/asxpdf/20240812/pdf/066j27mrjnft47.pdf